By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators discuss new findings in Oncology. According to news originating from Guangdong, People's Republic of China, by NewsRx correspondents, research stated, "Numerous studies have investigated the association between xeroderma pigmentosum complementation group C (XPC) poly (AT) deletion/insertion (PAT -/+) polymorphism and cancer susceptibility; however, the findings are inconsistent. Therefore, we performed a meta-analysis based on 32 publications including 10,214 cases and 11,302 controls to acquire a more robust estimation of the relationship."
Our news journalists obtained a quote from the research from the First Affiliated Hospital of Sun Yat-Sen University, "We searched publications from MEDLINE, EMBASE and CBM which assessed the associations between XPC PAT -/+ polymorphism and cancer risk. We calculated pooled odds ratio (OR) and 95% confidence interval (CI) by using either fixed-effects or random-effects model. We found that individuals carrying the PAT +/+ genotype have significantly increased cancer risk (PAT +/+ vs. OR=1.18, 95% CI=1.03-1.35 and recessive model: OR=1.19, 95% CI=1.06-1.33). Further stratification analysis showed a significantly increased risk for prostate cancer (PAT +/+ vs. OR=2.20, 95% CI=1.39-3.48, recessive model: OR=2.07, 95% CI=1.33-3.23 and PAT + vs. OR=1.39, 95% CI=1.12-1.71), bladder cancer (recessive model: OR=1.33, 95% CI=1.03-1.72), Caucasian ethnicity (recessive model: OR=1.21, 95% CI=1.02-1.43), population-based studies (recessive model: OR=1.23, 95% CI=1.05-1.43) and studies with relatively large sample size (PAT +/+ vs. OR=1.18, 95% CI=1.04-1.35 and recessive model: OR=1.20, 95% CI=1.08-1.33)."
According to the news editors, the research concluded: "Despite some limitations, this meta-analysis established solid statistical evidence for the association between the XPC PAT +/+ genotype and cancer risk, especially for urinary system cancer, but this association warrants further validation in single large studies."
For more information on this research see: Poly (AT) deletion/insertion polymorphism of the XPC gene contributes to urinary system cancer susceptibility: a meta-analysis. Gene, 2013;528(2):335-42. (Elsevier - www.elsevier.com; Gene - www.elsevier.com/wps/product/cws_home/506033)
The news correspondents report that additional information may be obtained from Q.S. Dai, Dept. of Oncology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510080, People's Taiwan. Additional authors for this research include R.X. Hua, R. Zhang, Y.S. Huang, Z.M. Hua, C.T. Yun, R.F. Zeng and J.T Long (see also Oncology).
Keywords for this news article include: Asia, Genetics, Oncology, Guangdong, Risk and Prevention, People's Republic of China, Metastatic Prostate Cancer.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .